MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
common stock from...
$46,517K
Proceeds from issuance of
pre-funded warrants from...
$14,156K
Proceeds from issuance of
common stock warrants...
$9,254K
Proceeds from issuance of
common stock under atm...
$6,054K
Proceeds from exercise of
stock options
$1,010K
Proceeds from espp
purchases
$164K
Maturities of marketable
securities
$120,000K
Net cash provided by
financing activities
$77,155K
Net cash provided by
investing activities
$35,595K
Canceled cashflow
$84,405K
Net increase
(decrease) in cash, cash...
$28,008K
Canceled cashflow
$84,742K
Stock-based compensation
expense
$14,317K
Accrued expenses and
other liabilities
$4,131K
Prepaid expenses and
other assets
-$4,031K
Non-cash lease expense
$1,551K
Depreciation expense
$1,129K
Other long-term
assets
-$47K
Other non-cash items
$27K
Purchases of marketable
securities
$83,958K
Purchases of property and
equipment
$447K
Net cash used in
operating activities
-$84,742K
Canceled cashflow
$25,233K
Net loss
-$106,191K
Accretion income on
marketable securities
$1,546K
Operating lease
liabilities
-$1,392K
Accounts payable
-$846K
Back
Back
Cash Flow
source: myfinsight.com
Aura Biosciences, Inc. (AURA)
Aura Biosciences, Inc. (AURA)